Multicenter registry study on proton radiotherapy of mediastinal lymphoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015660

Enrollment

300

Registered

2019-01-14

Start date

2018-08-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C85.2

Interventions

Group 1: Radiotherapy by means of protons in mediastinal lymphomas. Irradiation dose and sparing of organs at risk should be performed according to current guidelines or trials.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - histologically confirmed lymphoma according to WHO - informed consent - age = 18 years - Existence of the need for mediastinal radiotherapy and suspected benefit of mediastinal radiotherapy by protons compared to photon irradiation (e.g., improved sparing of heart, lungs and/or mamma compared to photon irradiation)

Exclusion criteria

Exclusion criteria: - Age <18 years - Non-consent of the patient to share his data - Revocation of the patient for study participation

Design outcomes

Primary

Measure	Time frame
long-term toxicity of proton radiotherapy	—

Secondary

Measure	Time frame
feasibility and efficacy for proton radiotherapy	—

Countries

Germany

Contacts

Public ContactLaila König

Universitätsklinikum Heidelberg; Abteilung für RadioOnkologie und Strahlentherapie

laila.koenig@med.uni-heidelberg.de06221 56 8201

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026